Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Intellia Therapeutics (NTLA) Prepaid Assets (2016 - 2025)

Historic Prepaid Assets for Intellia Therapeutics (NTLA) over the last 11 years, with Q3 2025 value amounting to $59.8 million.

  • Intellia Therapeutics' Prepaid Assets rose 3622.02% to $59.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $59.8 million, marking a year-over-year increase of 3622.02%. This contributed to the annual value of $29.8 million for FY2024, which is 3991.86% down from last year.
  • Per Intellia Therapeutics' latest filing, its Prepaid Assets stood at $59.8 million for Q3 2025, which was up 3622.02% from $36.8 million recorded in Q2 2025.
  • In the past 5 years, Intellia Therapeutics' Prepaid Assets ranged from a high of $59.8 million in Q3 2025 and a low of $14.0 million during Q3 2021
  • For the 5-year period, Intellia Therapeutics' Prepaid Assets averaged around $31.7 million, with its median value being $26.7 million (2022).
  • In the last 5 years, Intellia Therapeutics' Prepaid Assets skyrocketed by 22272.33% in 2021 and then tumbled by 3991.86% in 2024.
  • Intellia Therapeutics' Prepaid Assets (Quarter) stood at $18.6 million in 2021, then grew by 9.81% to $20.4 million in 2022, then surged by 143.3% to $49.7 million in 2023, then plummeted by 39.92% to $29.8 million in 2024, then skyrocketed by 100.62% to $59.8 million in 2025.
  • Its last three reported values are $59.8 million in Q3 2025, $36.8 million for Q2 2025, and $37.1 million during Q1 2025.